Lenalidomide Mylan

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
12-07-2023
Ciri produk Ciri produk (SPC)
12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
07-01-2021

Bahan aktif:

lenalidomide

Boleh didapati daripada:

Mylan Ireland Limited

Kod ATC:

L04AX07

INN (Nama Antarabangsa):

lenalidomide

Kumpulan terapeutik:

Immunosuppressants

Kawasan terapeutik:

Multiple Myeloma

Tanda-tanda terapeutik:

Multiple myelomaLenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).

Ringkasan produk:

Revision: 8

Status kebenaran:

Authorised

Tarikh kebenaran:

2020-12-18

Risalah maklumat

                                99
B. PACKAGE LEAFLET
100
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LENALIDOMIDE MYLAN 2.5 MG HARD CAPSULES
LENALIDOMIDE MYLAN 5 MG HARD CAPSULES
LENALIDOMIDE MYLAN 7.5 MG HARD CAPSULES
LENALIDOMIDE MYLAN 10 MG HARD CAPSULES
LENALIDOMIDE MYLAN 15 MG HARD CAPSULES
LENALIDOMIDE MYLAN 20 MG HARD CAPSULES
LENALIDOMIDE MYLAN 25 MG HARD CAPSULES
lenalidomide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Lenalidomide Mylan is and what it is used for
2.
What you need to know before you take Lenalidomide Mylan
3.
How to take Lenalidomide Mylan
4.
Possible side effects
5.
How to store Lenalidomide Mylan
6.
Contents of the pack and other information
1.
WHAT LENALIDOMIDE MYLAN IS AND WHAT IT IS USED FOR
Lenalidomide Mylan contains the active substance ‘lenalidomide’.
This medicine belongs to a group
of medicines which affect how your immune system works.
Lenalidomide Mylan is used in adults for:
•
Multiple myeloma
•
Myelodysplastic syndromes
•
Mantle cell lymphoma
•
Follicular lymphoma
MULTIPLE MYELOMA
Multiple myeloma is a type of cancer which affects a certain kind of
white blood cell, called the
plasma cell. These cells collect in the bone marrow and divide,
becoming out of control. This can
damage the bones and kidneys.
Multiple myeloma generally cannot be cured. However, the signs and
symptoms can be greatly
reduced or disappear for a period of time. This is called a
‘response’.
Newly diagnosed multiple myeloma – in patients who have had a bone
marrow transplant
Lenalidomi
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Lenalidomide Mylan 2.5 mg hard capsules
Lenalidomide Mylan 5 mg hard capsules
Lenalidomide Mylan 7.5 mg hard capsules
Lenalidomide Mylan 10 mg hard capsules
Lenalidomide Mylan 15 mg hard capsules
Lenalidomide Mylan 20 mg hard capsules
Lenalidomide Mylan 25 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Lenalidomide Mylan 2.5 mg hard capsules
Each capsule contains 2.5 mg of lenalidomide.
Lenalidomide Mylan 5 mg hard capsules
Each capsule contains 5 mg of lenalidomide.
Lenalidomide Mylan 7.5 mg hard capsules
Each capsule contains 7.5 mg of lenalidomide.
Lenalidomide Mylan 10 mg hard capsules
Each capsule contains 10 mg of lenalidomide.
Lenalidomide Mylan 15 mg hard capsules
Each capsule contains 15 mg of lenalidomide.
Lenalidomide Mylan 20 mg hard capsules
Each capsule contains 20 mg of lenalidomide.
Lenalidomide Mylan 25 mg hard capsules
Each capsule contains 25 mg of lenalidomide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule (capsule).
Lenalidomide Mylan 2.5 mg hard capsules
Green and white capsules, size 4, 14 mm, marked “MYLAN /LL 2.5”.
Lenalidomide Mylan 5 mg hard capsules
White capsules, size 2, 18 mm, marked “MYLAN/LL 5”.
Lenalidomide Mylan 7.5 mg hard capsules
Light grey and white capsules, size 2, 18 mm, marked
“MYLAN/LL7.5”.
Lenalidomide Mylan 10 mg hard capsules
Green and light grey capsules, size 0, 22 mm, marked “MYLAN/LL
10”.
Lenalidomide Mylan 15 mg hard capsules
White capsules, size 0, 22 mm, marked “MYLAN/LL15”.
3
Lenalidomide Mylan 20 mg hard capsules
Green and white capsules, size 0, 22 mm, marked “MYLAN/LL 20”.
Lenalidomide Mylan 25 mg hard capsules
White capsules, size 0, 22 mm, marked “MYLAN/LL 25”.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Multiple myeloma
Lenalidomide Mylan as monotherapy is indicated for the maintenance
treatment of adult patients with
newly diagnosed multiple myeloma who have undergone autologous st
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 12-07-2023
Ciri produk Ciri produk Bulgaria 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 07-01-2021
Risalah maklumat Risalah maklumat Sepanyol 12-07-2023
Ciri produk Ciri produk Sepanyol 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 07-01-2021
Risalah maklumat Risalah maklumat Czech 12-07-2023
Ciri produk Ciri produk Czech 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 07-01-2021
Risalah maklumat Risalah maklumat Denmark 12-07-2023
Ciri produk Ciri produk Denmark 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 07-01-2021
Risalah maklumat Risalah maklumat Jerman 12-07-2023
Ciri produk Ciri produk Jerman 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 07-01-2021
Risalah maklumat Risalah maklumat Estonia 12-07-2023
Ciri produk Ciri produk Estonia 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 07-01-2021
Risalah maklumat Risalah maklumat Greek 12-07-2023
Ciri produk Ciri produk Greek 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 07-01-2021
Risalah maklumat Risalah maklumat Perancis 12-07-2023
Ciri produk Ciri produk Perancis 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 07-01-2021
Risalah maklumat Risalah maklumat Itali 12-07-2023
Ciri produk Ciri produk Itali 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 07-01-2021
Risalah maklumat Risalah maklumat Latvia 12-07-2023
Ciri produk Ciri produk Latvia 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 07-01-2021
Risalah maklumat Risalah maklumat Lithuania 12-07-2023
Ciri produk Ciri produk Lithuania 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 07-01-2021
Risalah maklumat Risalah maklumat Hungary 12-07-2023
Ciri produk Ciri produk Hungary 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 07-01-2021
Risalah maklumat Risalah maklumat Malta 12-07-2023
Ciri produk Ciri produk Malta 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 07-01-2021
Risalah maklumat Risalah maklumat Belanda 12-07-2023
Ciri produk Ciri produk Belanda 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 07-01-2021
Risalah maklumat Risalah maklumat Poland 12-07-2023
Ciri produk Ciri produk Poland 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 07-01-2021
Risalah maklumat Risalah maklumat Portugis 12-07-2023
Ciri produk Ciri produk Portugis 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 07-01-2021
Risalah maklumat Risalah maklumat Romania 12-07-2023
Ciri produk Ciri produk Romania 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 07-01-2021
Risalah maklumat Risalah maklumat Slovak 12-07-2023
Ciri produk Ciri produk Slovak 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 07-01-2021
Risalah maklumat Risalah maklumat Slovenia 12-07-2023
Ciri produk Ciri produk Slovenia 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 07-01-2021
Risalah maklumat Risalah maklumat Finland 12-07-2023
Ciri produk Ciri produk Finland 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 07-01-2021
Risalah maklumat Risalah maklumat Sweden 12-07-2023
Ciri produk Ciri produk Sweden 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 07-01-2021
Risalah maklumat Risalah maklumat Norway 12-07-2023
Ciri produk Ciri produk Norway 12-07-2023
Risalah maklumat Risalah maklumat Iceland 12-07-2023
Ciri produk Ciri produk Iceland 12-07-2023
Risalah maklumat Risalah maklumat Croat 12-07-2023
Ciri produk Ciri produk Croat 12-07-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 07-01-2021

Cari amaran yang berkaitan dengan produk ini